Adage Capital Partners Gp, L.L.C. Biotechnology

Adage Capital Partners Gp, L.L.C.

$56.4 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
INSM Insmed Inc	$16.5B	$288 Million 0.51% of portfolio	2,859,452	Q2 2025 Reduced 17.04%
RPRX Royalty Pharma PLC	$15.7B	$216 Million 0.38% of portfolio	6,000,000	Q2 2025 Reduced 4.0%
ARGX Argenx Se	$35.3B	$164 Million 0.29% of portfolio	297,113	Q2 2025 Added 114.31%
IONS Ionis Pharmaceuticals Inc	$5.85B	$150 Million 0.27% of portfolio	3,800,000	Q2 2025 Added 253.29%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$114 Million 0.2% of portfolio	376,163	Q2 2025 Added 96.32%
CNTA Centessa Pharmaceuticals PLC	$1.61B	$110 Million 0.2% of portfolio	8,403,000	Q2 2025 Added 20.84%
WVE Wave Life Sciences Ltd.	$734M	$97.6 Million 0.17% of portfolio	15,016,500	Q2 2025 Added 19.97%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$79.3 Million 0.14% of portfolio	178,192	Q2 2025 Reduced 63.61%
ASND Ascendis Pharma A/S	$10.9B	$79.3 Million 0.14% of portfolio	459,606	Q2 2025 Added 40.38%
VRNA Verona Pharma PLC	$6.41B	$77.2 Million 0.14% of portfolio	816,715	Q2 2025 Reduced 49.93%
EYPT Eye Point Pharmaceuticals, Inc.	$366M	$64 Million 0.11% of portfolio	6,800,000	Q2 2025 Added 9.68%
PTGX Protagonist Therapeutics, Inc	$2.68B	$60.4 Million 0.11% of portfolio	1,092,262	Q2 2025 Added 217.98%
JANX Janux Therapeutics, Inc.	$1.01B	$58.3 Million 0.1% of portfolio	2,525,000	Q2 2025 Reduced 30.91%
AMLX Amylyx Pharmaceuticals, Inc.	$481M	$56.4 Million 0.1% of portfolio	8,800,000	Q2 2025 Added 54.45%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$55.6 Million 0.1% of portfolio	1,529,474	Q2 2025 Reduced 28.83%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$50.2 Million 0.09% of portfolio	95,630	Q2 2025 Added 3.11%
AXSM Axsome Therapeutics, Inc.	$4.51B	$46.7 Million 0.08% of portfolio	447,000	Q2 2025 Added 831.25%
NUVL Nuvalent, Inc.	$3.29B	$44.1 Million 0.08% of portfolio	577,500	Q2 2025 Added 45.47%
MRUS Merus N.V.	$2.93B	$43.8 Million 0.08% of portfolio	833,397	Q2 2025 New
RNA Avidity Biosciences, Inc.	$2.41B	$43.4 Million 0.08% of portfolio	1,527,000	Q2 2025 Reduced 28.84%
SRRK Scholar Rock Holding Corp	$1.66B	$43 Million 0.08% of portfolio	1,215,000	Q2 2025 Reduced 39.79%
TVTX Travere Therapeutics, Inc.	$1.12B	$41.2 Million 0.07% of portfolio	2,784,000	Q2 2025 Added 27.42%
XENE Xenon Pharmaceuticals Inc.	$2.24B	$40.4 Million 0.07% of portfolio	1,290,100	Q2 2025 Reduced 32.62%
MGTX Meira G Tx Holdings PLC	$361M	$39.3 Million 0.07% of portfolio	6,034,578	Q2 2025 Added 7.1%
OCUL Ocular Therapeutix, Inc	$961M	$36.1 Million 0.06% of portfolio	3,890,177	Q2 2025 Reduced 25.19%
FULC Fulcrum Therapeutics, Inc.	$340M	$31.6 Million 0.06% of portfolio	4,589,000	Q2 2025 Added 52.97%
AURA Aura Biosciences, Inc.	$203M	$30.6 Million 0.05% of portfolio	4,881,125	Q3 2024 Reduced 0.08%
DYN Dyne Therapeutics, Inc.	$602M	$30.4 Million 0.05% of portfolio	3,191,000	Q2 2025 New
TNGX Tango Therapeutics, Inc.	$595M	$30.2 Million 0.05% of portfolio	5,905,349	Q2 2025 New
PTCT Ptc Therapeutics, Inc.	$3.24B	$29.6 Million 0.05% of portfolio	605,905	Q2 2025 Added 1.83%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$27.5 Million 0.05% of portfolio	84,390	Q2 2025 Reduced 70.09%
AGIO Agios Pharmaceuticals, Inc.	$1.94B	$26.3 Million 0.05% of portfolio	791,000	Q2 2025 Added 6.46%
IDYA Ideaya Biosciences, Inc.	$1.13B	$26 Million 0.05% of portfolio	1,238,094	Q2 2025 Added 4.21%
ROIV Roivant Sciences Ltd.	$8.15B	$23.5 Million 0.04% of portfolio	2,082,383	Q2 2025 Reduced 45.49%
TARS Tarsus Pharmaceuticals, Inc.	$1.37B	$22 Million 0.04% of portfolio	543,000	Q2 2025 Added 6.47%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$21.5 Million 0.04% of portfolio	341,000	Q2 2025 New
KMPH Kempharm, Inc	$170M	$20.6 Million 0.04% of portfolio	4,168,000	Q2 2025 Added 15.2%
ETNB 89bio, Inc.	$420M	$19.3 Million 0.03% of portfolio	1,969,000	Q2 2025 New
ABEO Abeona Therapeutics Inc.	$38M	$17.5 Million 0.03% of portfolio	3,072,985	Q2 2025 Added 14.17%
HRTX Heron Therapeutics, Inc.	$156M	$16.3 Million 0.03% of portfolio	7,852,000	Q1 2025 Reduced 7.62%
PGEN Precigen, Inc.	$375M	$16 Million 0.03% of portfolio	11,276,000	Q1 2025 Added 3.78%
AKRO Akero Therapeutics, Inc.	$2.23B	$15.7 Million 0.03% of portfolio	295,000	Q2 2025 Added 51.28%
VRDN Viridian Therapeutics, Inc.\De	$717M	$15.5 Million 0.03% of portfolio	1,108,586	Q2 2025 Reduced 0.54%
RVMD Revolution Medicines, Inc.	$3.09B	$14.6 Million 0.03% of portfolio	397,400	Q2 2025 Added 0.86%
JAZZ Jazz Pharmaceuticals PLC	$7.1B	$14.3 Million 0.03% of portfolio	135,037	Q2 2025 Added 938.75%
TECH Bio Techne Corp	$2.07B	$13.8 Million 0.02% of portfolio	268,600	Q2 2025 Reduced 8.73%
PRQR Pro Qr Therapeutics N.V.	$136M	$13.5 Million 0.02% of portfolio	6,601,938	Q2 2025 Reduced 18.52%
CABA Cabaletta Bio, Inc.	$38.6M	$13.4 Million 0.02% of portfolio	8,829,758	Q2 2025 Added 142.94%
SNDX Syndax Pharmaceuticals Inc	$734M	$13.4 Million 0.02% of portfolio	1,432,440	Q2 2025 Added 126.78%
KYMR Kymera Therapeutics, Inc.	$2.18B	$13.3 Million 0.02% of portfolio	304,200	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.